Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Sexually Transmitted Diseases 1Papillomavirus Infections 1Lung Neoplasms 1Condylomata Acuminata 1Carcinoma, Non-Small-Cell Lung 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 36Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 19Papillomavirus Vaccines 16Vaccines 10Data Collection 9Blood Specimen Collection 5Vaccines, Synthetic 4artesunic acid 3artemisinin 3Engerix-B 3halofantrine 2epigallocatechin gallate 2artenimol 2Hepatitis A Vaccines 2GX-188 vaccine 2Colposcopy 2ranpirnase 1fludarabine 1Viusid 1Vitamin B 12 1VP-102 1VGX-3100 1Therapies, Investigational 1Sodium Chloride 1Pentetic Acid 1Observation 1Methods 1Measles-Mumps-Rubella Vaccine 1Interleukin-2 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Papillomavirus Infections × ranpirnase × Clear all
NCT02535104 2018-06-06

Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)

Tamir Biotechnology, Inc.

Phase 1/2 Completed
70 enrolled

Condylomata Acuminata, Sexually Transmitted Diseases, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡